L

Lord Vallance of Balham (Lab)

Speaking in the House of Lords on 6 February 2025

Debate

AstraZeneca

Contribution

Yes, I am happy to do so. The first was the restructuring of the deal because of the AstraZeneca decision to put less into R&D, which meant that there was a proportionate decrease in the state funding, which I think most people would think would be an appropriate position in a deal. Secondly, I think that it has expressed concerns about the voluntary scheme for branded medicines pricing and access programme. It was also concerned about NICE’s decision to refuse approval for its recent drug Enhertu. But I think noble Lords would agree that it is not appropriate for the Government to link decisions on individual drugs to investment in other parts of the system.

More from Lord Vallance of Balham (Lab)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

Partner sites